I'm LongbridgeAI, I can summarize articles.Enliven Therapeutics CMO Helen Louise Collins sold 5,000 common shares for approximately USD 262,213. The transaction involved exercising stock options at $2.48 and selling the shares between $49.72 and $53.93 on July 17, 2026. Post-transaction, Collins holds 25,000 common shares and 116,268 stock options expiring in June 2031.
- Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares at $2.48 on July 17, 2026. * Collins sold 5,000 shares in multiple transactions at prices ranging from $49.72 to $53.93. * Beneficial ownership following the transactions: 25,000 shares of common stock. * Derivative holdings following the transactions: 116,268 stock options with a $2.48 exercise price, expiring June 17, 2031. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701247-26-000011), on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here